Patents Examined by Jia-Hai Lee
  • Fragment ligated inhibitors selective for the polo box domain of PLK1
    Patent number: 10067131
    Abstract: Methods for developing non-peptidic inhibitors that target the polo-box domain of PLK1 proteins are described. Methods include developing structure activity relationships for peptidic inhibitors followed by development of non-peptide fragment alternatives for portions of the peptide inhibitors. The non-peptide fragment can provide similar structure activity relationship as the replaced peptide. Fragment alternatives to key binding determinants are identified in an iterative computational and synthetic process facilitated through understanding of the peptide structure-activity relationships. The approach is informed by peptide structure-activity data obtained through synthesis and testing of truncated and mutated analogs of known PBD binding motifs.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: September 4, 2018
    Assignee: University of South Carolina
    Inventors: Campbell McInnes, Doaa Boshra Farag
  • Compositions and methods for immune tolerance induction
    Patent number: 10064922
    Abstract: Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as Factor VIII or any other protein or peptide) complexed with liposomes comprising PS and PC (PS liposomes), or comprising PS, PI and PC and, optionally, cholesterol (PS/PI liposomes) may be used.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: September 4, 2018
    Assignee: The Research Foundation for The State University of New York
    Inventor: Sathy V. Balu-Iyer
  • Method of making a skin care product
    Patent number: 10058495
    Abstract: A method of making a skin care product that includes a skin care composition containing a skin care active with a diamagnetic susceptibility of between about ?400 and ?600, constructing an applicator for applying the skin care composition to a target portion of skin, and packaging the composition and applicator for retail sale. The applicator includes a magnetic array tailored to enhance penetration of the skin care active into skin. The magnetic array may be unidirectional magnetic array or a bi-directional magnetic array.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 28, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Rosemarie Osborne, Matthew James Mcildowie, Jeffrey David Edwards
  • Long-acting peptide analogs
    Patent number: 10058592
    Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: August 28, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Sheau Yu Hsu, Chia Lin Chang
  • Hemostatic compositions
    Patent number: 10046034
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 14, 2018
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Therapeutic agent delivery system and method
    Patent number: 10045937
    Abstract: A therapeutic agent delivery system includes a therapeutic agent delivery platform and a therapeutic guest agent. The therapeutic agent delivery platform is capable of being implanted in a tissue being treated. The platform includes a substrate and at least one host molecule coupled to the substrate. The therapeutic guest agent is capable of reversibly coupling with the host molecule when administered to the tissue being treated. The reversible coupling is defined by the binding affinity between the host molecule and the therapeutic guest agent. The therapeutic guest agent is delivered at a rate determined by the affinity release rate between the host molecule and the therapeutic guest agent. The degradation rate of the therapeutic guest agent may be slower than the affinity release rate between the host molecule and the therapeutic guest agent.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 14, 2018
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Horst A. von Recum, Julius N. Korley
  • Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
    Patent number: 10046060
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 14, 2018
    Assignee: NoNO INC.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Method for producing a composition for treating a tooth lesion
    Patent number: 10047120
    Abstract: The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralizing a tooth lesion such as a subsurface caries lesion.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: August 14, 2018
    Assignee: Credentis AG
    Inventors: Michael Hug, Dominikus Amadeus Lysek
  • Selective photoactivation of amino acids for single step peptide coupling
    Patent number: 10040818
    Abstract: Disclosed herein are formulations, substrates, and arrays for amino acid and peptide synthesis on microarrays. In certain embodiments, methods for manufacturing and using the formulations, substrates, and arrays including one-step coupling, e.g., for synthesis of peptides in a C?N orientation are disclosed. In some embodiments, disclosed herein are formulations and methods for high efficiency coupling of biomolecules to a substrate.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: August 7, 2018
    Assignee: Vibrant Holdings, LLC
    Inventor: Vasanth Jayaraman
  • Skin care product and method of use
    Patent number: 10034827
    Abstract: A cosmetic skin care product that includes an applicator and a skin care composition. The applicator includes a uni-directional magnetic array with a pitch of between 1.7 and 2.5 and a magnetic field strength of between about 24.0 and 36.0 mT. The skin care composition includes palmitoyl-lysine-threonine-threonine-lysine-serine and a dermatologically acceptable carrier. The magnetic array is tailored to enhance penetration of the Pal-KTTKS into skin during application of the skin care composition. The applicator may include a second magnetic array juxtaposed on a first magnetic array to form a bi-directional array that enhances penetration of the Pal-KTTKS into skin.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: July 31, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Rosemarie Osborne, Matthew James McIldowie, Jeffrey David Edwards
  • Method for producing synthetic pentapeptide
    Patent number: 10035767
    Abstract: Provided are a method for industrially advantageously producing a highly purified pentapeptide and an intermediate thereof. A compound represented by the following formula (1) or a salt thereof: wherein R1 represents an alkyl group or an aralkyl group.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 31, 2018
    Assignee: MARUISHI PHARMACEUTICAL CO., LTD.
    Inventors: Asami Murayama, Takaaki Kano
  • Luminate eye gel
    Patent number: 10034825
    Abstract: The present invention features novel cosmetic skin care compositions for improving the appearance of skin, particularly the periocular region.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: July 31, 2018
    Assignee: Jan Marini Skin Research
    Inventors: Jan L. Marini, Subhash J. Saxena
  • Method for treatment of GM1 gangliosidosis
    Patent number: 10035830
    Abstract: The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 31, 2018
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Yee Sook Cho, Mi Young Son, Jae Eun Kwak, Binna Seol, Hye Jin Jeon
  • Stable helical ionic polypeptides
    Patent number: 10030103
    Abstract: The invention provides polymers comprising Formula I: wherein monomer is a repeating unit comprising 2, 3, 4, 5, 6 or 7 carbon atoms and the monomers are linked together through amide or ester bonds; n is about 6 to about 1000; and Linker is an optionally substituted carbon chain that is optionally interrupted by moieties such as oxygen, nitrogen, sulfur, phosphorus, or silicon. Charge is a moiety having a positive or negative charge on a heteroatom, such as nitrogen, oxygen, phosphorus, or sulfur; where the Linker separates the monomer and the Charge by at least six linear atoms. The invention also provides methods of preparing the polymers and the copolymers and methods of using the polymers and copolymers, for example, as drug delivery systems, as membrane penetrating peptides, and as therapeutic agents.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: July 24, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Jianjun Cheng, Hua Lu
  • Stabilisation of polypeptides
    Patent number: 10029007
    Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: July 24, 2018
    Assignee: Stabilitech Biopharma Ltd
    Inventors: Jeffrey Drew, David Thomas Woodward, Stephen Ward
  • Diaspirin crosslinked pegylated hemoglobin
    Patent number: 10029001
    Abstract: PEGylated diaspirin-crosslinked hemoglobin conjugates having high oxygen affinity are described which have enhanced nitrite reductase activity to deliver oxygen, carbon monoxide, nitric oxide or mixtures thereof to tissues to treat various diseases and conditions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 24, 2018
    Inventor: William Schindler
  • Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
    Patent number: 10029012
    Abstract: The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: July 24, 2018
    Assignee: UNIVERSITY OF PITTSUBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Pradeep Tyagi, Naoki Yoshimura, Mahendra Pratap Kashyap
  • Process for the preparation of bortezomib mannitol ester
    Patent number: 10023611
    Abstract: A novel and improved process for preparation of bortezomib mannitol ester is derived, which process avoids excessive use of solvents, involves convenient, industrially feasible and economical techniques, and provides improvements in purity over processes known in the art.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: July 17, 2018
    Assignee: Cipla Limited
    Inventors: Ravikumar Puppala, Srinivas Laxminarayan Pathi, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Fast dissolving pharmaceutical composition
    Patent number: 10023335
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: July 17, 2018
    Assignee: Ferring B.V.
    Inventors: Shweta Gupta, Varinder Ahuja, Tejas Gunjikar, Kristin Wannerberger
  • Peptide pharmaceuticals
    Patent number: 10010617
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: July 3, 2018
    Assignee: EUMEDERIS PHARMACEUTICALS, INC.
    Inventor: John J. Nestor